CoChat
Sign Up
Cited by 692

The DOI matches its Crossref record.

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators

McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., Maggioni, A., Young, J., Pogue, J.·1999·Circulation
DOI 10.1161/01.cir.100.10.1056
Open this paper in CoChat — free account

Abstract

Background —We investigated the effects of candesartan (an angiotensin II antagonist) alone, enalapril alone, and their combination on exercise tolerance, ventricular function, quality of life (QOL), neurohormone levels, and tolerability in congestive heart failure (CHF). Methods and Results —Seven hundred sixty-eight patients in New York Heart Association functional class (NYHA-FC) II to IV with ejection fraction (EF) <0.40 and a 6-minute walk distance (6MWD) <500 m received either candesartan (4, 8, or 16 mg), candesartan (4 or 8 mg) plus 20 mg of enalapril, or 20 mg of enalapril for 43 weeks. There were no differences among groups with regard to 6MWD, NYHA-FC, or QOL. EF increased ( P =NS) more with candesartan-plus-enalapril therapy (0.025±0.004) than with candesartan alone (0.015±0.004) or enalapril alone(0.015±0.005). End-diastolic (EDV) and end-systolic (ESV) volumes increased less with combination therapy (EDV 8±4 mL; ESV 1±4 mL; P <0.01) than with candesartan alone (EDV 27±4 mL; ESV 18±3 mL) or enalapril alone (EDV 23±7 mL; ESV 14±6 mL). Blood pressure decreased with combination therapy (6±1/4±1 mm Hg) compared with candesartan or enalapril alone ( P <0.05). Aldosterone decreased ( P <0.05) with combination therapy (23.2±5.3 pg/mL) at 17 but not 43 weeks compared with candesartan (0.7±7.8 pg/mL) or enalapril (−0.8±11.3 pg/mL). Brain natriuretic peptide decreased with combination therapy (5.8±2.7 pmol/L; P <0.01) compared with candesartan (4.4±3.8 pmol/L) and enalapril alone (4.0±5.0 pmol/L). Conclusions —Candesartan alone was as effective, safe, and tolerable as enalapril. The combination of candesartan and enalapril was more beneficial for preventing left ventricular remodeling than either candesartan or enalapril alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.100.10.1056

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 15

  1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;326:1429–1435.
  2. 10.1056/NEJM199108013250501 · DOI · Paper page
  3. 10.1016/0002-8703(88)90333-X · DOI
  4. 10.1161/circ.91.7.2043 · DOI
  5. Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni A, McKelvie RS, Wiecek EW, Wang Y, Pogue J, Teo KK, White M, Avezum A, Latini R, Held P, Lindgren E, Probstfield J, for the RESOLVD Pilot Study Investigators. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997;13:1166–1174.
  6. 10.1016/0002-9149(93)90582-W · DOI
  7. 10.1016/0735-1097(95)80020-H · DOI
  8. 10.1016/S0735-1097(97)00253-2 · DOI
  9. 10.1016/S0140-6736(97)01187-2 · DOI
  10. 10.1097/00005344-199710000-00020 · DOI
  11. 10.1161/circ.96.7.2385 · DOI
  12. 10.1161/circ.82.5.2146040 · DOI
  13. 10.1161/circ.82.5.2225374 · DOI
  14. 10.1161/circ.91.3.691 · DOI
  15. Gottlieb SS Dickstein K Fleck E Kostis J Levine TB LeJemtel T Dekock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88(pt 1):1602–1609. · DOI

Cited by

Sorted by citations

Metadata

Authors
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., Maggioni, A., Young, J., & Pogue, J.
Affiliations
From Hamilton Health Sciences Corporation–General Division, and McMaster University, Hamilton, Ontario, Canada (R.S.M., S.Y., D.P., J. Pogue); Dante Pazzanese Cardiology Institute, Sao Paulo, Brazil (A.A.); Toronto Hospital–Western Division, Toronto, Ontario, Canada (R.J.B.); Fred Hutchinson Cancer Center, Seattle, Wash (J. Probstfield); University of Alberta Hospitals, Edmonton, Alberta, Canada (R.T.T.); Montreal Heart Institute, Montreal, Quebec, Canada (M.W., J.R.); Istituto di Ricerche...
Venue
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
1999-09-07
Volume
100
Issue
10
Pages
1056-1064
ISSN
  • 0009-7322
  • 1524-4539
DOI
10.1161/01.cir.100.10.1056
Cited by
692
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review